| 黄三钱 钟晶敏 李晶 刘志红 曾亮.乳腺癌分子分型的研究进展[J].,2016,16(22):4384-4387 |
| 乳腺癌分子分型的研究进展 |
| Advances in Breast Cancer Molecular Typing |
| |
| DOI： |
| 中文关键词: 分子分型 乳腺癌 雌激素 孕激素 上皮生长因子受体2 |
| 英文关键词: Molecular typing Breast cancer Estrogen Progesterone Epithelial growth factor receptor 2 |
| 基金项目:湖南省科技计划项目（2014FJ6090） |
|
| 摘要点击次数: 839 |
| 全文下载次数: 0 |
| 中文摘要: |
| 乳腺癌是目前世界上女性最为常见的恶性肿瘤之一。随着个体化的乳腺癌的化疗、内分泌治疗和靶向治疗的广泛使用，乳
腺癌的分子分型检测也因此得到高度重视和广泛使用。2013 年St. Gallen 国际乳腺癌会议上重新定义了乳腺癌的分子分型标准，
使Luminal A 型和Luminal B型乳腺癌的比例有所改变，导致原本分类为Luminal A型的部分患者重新分类为Luminal B型而使
Luminal B型患者数量有所增加。人上皮生长因子受体-2(human epidermalgrowth factor receptor-2, HER2)型乳腺癌的靶向药物曲
妥珠单抗与其他化疗药物的联合应用及不同时间应用的治疗效果有了进一步研究。雄激素受体（Androgen Receptor，AR）认为可
用于常规评估三阴性乳腺癌，除此之外，三阴性乳腺癌的小亚型的分型也为三阴性乳腺癌的个体化治疗提供了新的思路。尽管乳
腺癌分子分型方面已取得一定进展，并获得国际同行间的认可，给乳腺癌患者的治疗和预后复发预测提供了重要依据，但目前所
有的分子标记物仍不能够满足治疗需求使其临床实用性仍旧具有局限性，因此还期待更多更深入的研究。 |
| 英文摘要: |
| Breast cancer is currently one of the most common female malignant tumors in the world .With the widespread use of
individualized breast cancer chemotherapy, hormonal therapy and targeted therapy, the molecular typing of breast cancer detection
therefore highly valued and widely used. 2013 St. Gallen International Breast Cancer Conference redefined the standard of molecular
typing of breast cancer, and made the proportion of Luminal A and Luminal B breast cancer have changed, resulting in some patients
originally classified as Luminal A type reclassified as Luminal B-type, leaving Luminal B-type increase in the number of patients.
Combined HER2（human epidermal growth factor receptor-2）breast cancer targeted drug trastuzumab with chemotherapy drugs and
other treatment applications at different times has been further study. AR (androgen receptor) considered for routine assessment of
triple-negative breast cancer, in addition, the classification about triple negative breast cancer small subtype has provided new thinking
for individualized treatment of triple-negative breast cancer. Although the molecular typing of breast cancer has made some progress and
get international recognition among peers, providing an important basis to the prediction of the treatment and prognosis of breast cancer
relapse, all of the molecular markers we used is still not able to meet all the treatment needs, therefore it still has limitations to the clinical
utility.We need in-depth study about it . |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
